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Abstract  
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Aim: 
 
To study the utility of Lugol’s iodine in achieving tumour free surgical margins 
in squamous cell carcinoma of the oral cavity. 
 
Objectives: 
(1)  To determine whether the use of Lugol’s iodine resulted in reduced 
incidence of involved and close surgical margins, in squamous cell 
carcinoma of the oral cavity. 
 (2) To determine whether the use of Lugol’s iodine enabled the surgeon to 
visualize the tumour extent better compared to clinical examination alone. 
 
(3)  To study the staining patterns observed following local application of 
Lugol’s iodine in squamous cell carcinoma of the oral cavity. 
 
(4)  To look for association between the various staining patterns and the 
incidence of involved and close resection margins on final 
histopathology. 
 
Materials and methods:  
We evaluated the use of  Lugol’s iodine in achieving surgical margins free of 
dysplasia or invasive carcinoma by an observational study of two sets of 
patients who underwent resection for oral carcinoma between 15.05.10 – 
15.06.11 and from 15.09.12  to 15.10.13.  The patients in the second group 
underwent staining with 1.25% Lugol’s iodine as per the described procedure.  
The patterns of staining were noted and the margins on clinical examination and 
following Lugol’s staining were compared.   Resection was left to the surgeons 
discretion.  Margin status was compared with the retrospective cohort of 60 
patients operated over a similar duration. 
 
Results: 
90 patients underwent resection in the study period between 15.09.12  to 
15.10.13, of which data from 30 patients was available for analysis .  The 
incidence of close and positive margins decreased significantly (17% vs 37% 
and 6% vs 38% respectively) in the cohort where Lugol’s iodine was used (p = 
0.000).   
Conclusion: 
With appropriate patient selection, staining with Lugol’s iodine appears to be a 
promising method of obtaining tumour free resection margins in carcinoma of 
the oral cavity.  However, studies with a larger sample size and randomization 
are required to further establish it’s utility. 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
  
Head and neck malignancies are the sixth most common of all malignancies 
worldwide, squamous cell carcinoma accounting for 95% of them.   In the 
Indian subcontinent however, it is overall, the most common cancer.   In terms 
of frequency, it ranks first among the male population and third among the 
female population.  The reason for this increased incidence can be attributed to 
the habit of chewing paan, khaini and other forms of smokeless tobacco, 
peculiar to this geographical location, which in addition to alcohol and smoking, 
has been identified as one of the major risk factors in the development of oral 
malignancies.  
  
The 5 year survival has been reported to be 58%  among the Caucasian 
population and 45 – 49% in the European population (1).   In contrast, Indian 
statistics cite a 5 year survival of approximately 30%, likely due to the higher 
proportion of advanced disease at presentation in these patients.   Apart from the 
high mortality rate, oral malignancies pose a significant therapeutic challenge 
due to the high rate of local recurrence and the incidence of second primaries 
within the oral cavity, pharynx, oesophagus and respiratory tract.   
 
Many factors have been identified, that are associated with increased likelihood 
of recurrence.   Most of these factors are related to tumour biology, stage of the 
disease and final histopathology following excision.  Of particular note among 
these, is the presence of close (invasive carcinoma < 4mm from the resection 
margin) or involved margins (invasive carcinoma at the resection margin), 
which has been reported to have a significant association with increased local 
recurrence rates and decreased 5 year survival.  The presence an inadequate 
margin alone, of all the identified adverse risk features, is within the direct 
control of the surgeon and thereby amenable to modification by variation in 
treatment strategies.   
 
Furthermore, it is one of the factors which dictate the need for adjuvant therapy.   
Current management protocols, as described in the NCCN (National 
Comprehensive Cancer Network) guidelines for management of carcinoma of 
the oral cavity, state that the presence of close or involved resection margins in 
any one direction requires the addition of radiation therapy.  Hence, in early 
lesions (stage I, II) where surgical resection alone would normally suffice, the 
presence of inadequate surgical resection margins necessitates the addition of a 
second modality of treatment, namely radiotherapy.  As radiotherapy to the 
head and neck region can be administered only a single time, this results in the 
utilization of a therapeutic modality which could otherwise be held in reserve 
for recurrences or second primaries. 
 
Additionally, though the use of postoperative radiotherapy administered to 
patients with close or involved resection margins decreased local recurrence 
rates, it was unable to match the local recurrence rates of those who had 
adequate margins in the first instance.  Also, in these instances, although 
postoperative radiotherapy decreased local recurrence rates significantly, it did 
not impact five year survival (2), (3).  The presence of inadequate resection 
margins also necessitates prolonged hospital stay due to wound complications, 
re- excision and additional chemoradiation.   In a developing country like India 
where the burden of this disease is high, the financial implications are likewise, 
significant. 
 
Various solutions have been sought to decrease the incidence of inadequate 
surgical resection margins.  These include the use of imaging modalities 
preoperatively, frozen sections to determine adequacy of the margin intra-
operatively and the use of an optical spectroscope for better visualization of 
malignant tissue, to aid complete resection.  Of particular interest is the use of 
vital dyes including toludine blue and Lugol’s iodine for staining malignant 
tissue.  These dyes stain malignant tissue a different colour from normal tissue.  
They can be used as an adjunct to clinical examination in identifying the 
presence and extent of malignant tissue intra-operatively and to better delineate 
lesions unclear on clinical examination, thereby improving completeness of 
resection.   
 
Another attempt at decreasing the incidence of inadequate margins involves 
excising a wider margin of normal tissue surrounding the malignancy.  The 
optimal margin of resection has been debated.  This poses a significant 
challenge in oral malignancies, given the limited space and the functional 
aspects of the oral cavity.   A smaller margin of excision leaves to question the 
adequacy of resection margins, especially after allowing for post excisional and 
post fixation shrinkage of tissue.  A minimum of 1 cm circumferential margin of 
normal tissue is required to ensure the adequacy of resection margins.  
However, excision of a larger margin of tissue within the oral cavity will cause 
greater compromise of oral functions including speech, swallowing, mouth 
opening and continence of the oral commissure, as well as greater cosmetic 
deformity.  Additionally, given the high proportion of advanced lesions at 
presentation, larger excision margins will result in larger defects, requiring the 
employment of increasingly complex options in the reconstruction ladder, for 
closure of the defect.  This will require additional operating time and financial 
support, which, in a country where resources are limited, becomes an important 
factor in deciding treatment.  The ideal margin, which is a balance between 
these considerations, is a matter of debate and a consensus as to the optimal 
margin is yet to be reached. 
 
In our institution, we operate on approximately 60 cases of malignancies of the 
oral cavity each year.  Looking into the incidence of close and involved margins 
in our institution, it was found to be 44% for close margins and 34% for 
involved margins.   When compared to the incidence rates reported worldwide - 
approximately 20 – 43 % for close margins and  ranged from 11-32%  involved 
margins (2), (4), (5), (6) - it was clear that further steps were required  to 
decrease this relatively high rate of inadequate margins.   
 
After debating the available options and the feasibility of each in our setting, it 
was decided to use Lugol’s iodine to stain the lesion in a bid to better visualize 
abnormal tissue and thereby decrease the incidence of inadequate resection 
margins.  Lugol’s iodine was preferred due to the wide availability, simple 
procedure, reproducibility, low cost, few side effects and minimal additional 
time required.  Following staining with Lugol’s iodine, the close and involved 
margin rates were re-examined for change and the observed findings constitute 
this thesis.  
 
 
 
 
 
                                                  
  
  
 
 
 
 
 
 
 
 
Literature review 
Oral malignancies are of particular relevance in the Indian subcontinent, by 
virtue of sheer numbers.  In this geographical location, the incidence is far more 
frequent compared to the overall global incidence, making it the most common 
cancer in India.  This fact alone indicates the need of further efforts to control 
and mitigate the effects of this disease. (7) 
 
Furthermore, a significant proportion of malignancies of the oral cavity occurs 
in people of the lower socioeconomic strata, likely due to the habit of chewing 
khaini or paan, a potent carcinogen.  Compared to Western literature,where  
patients present early in the course of the disease, in India, a significant 
proportion of patients tend to present with advanced stages.  Hence, therapy 
frequently involves extensive resection with relatively complicated 
reconstructive procedures and usually requires additional radiation or 
chemotherapy.   Taking into account the fact that most of these patients are 
unlikely to be covered by health insurance and that the existing government 
schemes cannot provide adequate relief, the financial demands of treatment on 
these patients becomes a significant consideration in their treatment.  It is hence 
of paramount importance that further steps are taken to address this problem.  
Anatomy: 
The oral cavity extends from the vermillion border of the lips upto the 
circumvallate papilla, which demarcates the anterior two- thirds of the tongue - 
part of the oral cavity - from the posterior thirds, which forms a part of the 
oropharynx. 
It includes the following subdivisions: 
 Lip 
 Buccal mucosa 
 Anterior tongue 
  Alveolus 
  Floor of mouth 
  Retromolar  trigone  
  Hard palate 
 
Epidemiology: 
In 2008, Jemal et al reported the worldwide incidence of malignancies of the 
oral cavity to be 263,900, causing 128,000 deaths.   The geographical 
distribution of oral cavity malignancies is uneven, with two thirds of all cases 
occurring in developing countries, predominantly in South East Asia.  Reported 
age standardized incidence rates varied from 9.4 and 5.5 among males and 
females respectively in South East Asia, to a corresponding 5.1 and 2.8  in 
Northern Europe (8) .   SEER (Surveillance, Epidemiology and End Results 
program) database statistics of 2013 reported an incidence of 10.8 new cases per 
100,000 men and women, causing 2.5 deaths per 100,000 of the population.  
This comprised 1.4 % of all cancer deaths in the United States of America.   In 
terms of proportion among all cancers, it accounts for 30% of all cancers in 
India, as opposed to 3% in the UK and 6% in France (International agency for 
research on cancer WHO). 
 
Asia, particularly India, is home to 57.5% of all head and neck cancers.  The 
annual incidence of head and neck cancers in India alone is greater than 
200,000.  It is the most common cancer among Indian males, accounting for 
30% of all malignancies (74), (75).  Among Indian females, it ranks third in 
order of frequency, following carcinoma of the cervix and breast, and accounts 
for 16% of all malignancies (9) 
 
 Demographic profiling shows that the mean age at diagnosis is 63 years.   It 
occurs more commonly in males, with a male: female – 2.42:1.  The burden of 
this disease falls on the lower and lower middle classes of the population.  
Histopathological examination shows that 90- 95% of all oral malignancies fall 
under the category of squamous cell or epitheliod carcinoma.  The most 
common sites of occurrence are the tongue and buccal mucosa.   Involvement of 
the floor of mouth and lip are usually due to contiguous spread from adjacent 
areas, as primary malignancies at these sites are relatively less common.   In 
India, 60-80% of patients present with advanced stages of the disease (stage III, 
IV) as opposed to 40 % of patients in developed countries (10).  The differences 
in the prevalence of use of carcinogenic agents likely accounts for some of the 
demographic differences, as is evidenced by the use of paan in the Indian 
subcontinent and the increased use of tobacco and alcohol among males 
irrespective of geographical location. 
 
Risk factors: 
The development of malignancy in the oral cavity is attributed almost 
exclusively to the major risk factors, which include smoking, alcohol 
consumption and the use of smokeless tobacco.  Other identified risk factors 
include human papilloma virus infection, consumption of spicy food, poor oral 
hygiene, periodontal disease  and repeated trauma due to the presence of sharp 
facets on adjacent teeth (11). Hereditary factors have little or no role to play in 
the etiology and pathogenesis of oral carcinomas.    Dietary factors including 
high vegetable and fish consumption were noted to have a protective effect in 
sporadic trials. 
Heavy cigarette smoking increased the risk of developing cancer to 5 – 25 times 
that of  similarly matched non smokers  (12), (13), (14).  The relative risk in 
smokers was reported to be 6.5 (15).  The strength of association between 
smoking and development of malignancy was directly proportional to the 
duration of smoking and number of cigarettes per day.   Tobacco being the 
active principle predominantly responsible causing malignancy, there was no 
difference between those smoking cigarettes, cigars or pipes.   Cessation of 
smoking reduced the relative risk of developing cancer, however, it was 
equivalent to non smokers only after 20 years.  
 
Alcohol consumption independently increased the risk of developing oral 
cancer, the relationship being more pronounced in those who consumed larger 
quantities.   It was noted by Stefani et al that regular consumption of 50g of 
alcohol per day increased the risk of  developing oral cavity cancer by 5 -  6 
times, compared to those who consumed less than 10g per day (16).   Apart 
from the independent effect in causing cancer, alcohol also showed a 
synergistic, almost  multiplicative effect, when added to smoking (15) (17).   
 
Paan, khaini and gutkha are various forms of smokeless tobacco available in the 
Indian subcontinent.  They contain variable combinations of betel leaves, areca 
nut, tobacco and slaked lime and are used in different forms, for either chewing 
or inhalation (18).  Both forms are implicated in the development of oral cavity 
malignancy and are in part responsible for it’s increased incidence  in this 
geographical location  (19).    
 
 Though tobacco and alcohol were established risk factors for development of 
malignancies of the head and neck region, investigators noted, however, that 
despite a decrease in the prevalence of both, the  incidence and prevalence rates 
of oral and oropharyngeal cancer failed to show a corresponding trend.  
Additional risk factors were sought and this led to the emergence of human 
papilloma virus (HPV) infection as an added risk factor contributing to 
carcinogenesis in these sites.   The prevalence of  HPV  in the oral cavity was 
noted to be 10.1 % in men and 3.6% in women, resulting in an overall 
prevalence of 6.9% (20).   Based initially on the study of epidemiological 
patterns, followed by molecular evidence, HPV has been causally linked to the 
development of carcinoma of the head and neck region.  HPV DNA was 
detected in 10% and 37% of oral cavity and oropharyngeal carcinomas, 
respectively (21) .  The predominant subtypes were HPV16, 18 and 33.  HPV 
associated cancers occurred 10 years earlier on an average and were less likely 
to be associated with second primaries (22). 
 
 
Premalignant lesions: 
Premalignant lesions are, by definition, those lesions which presently do not 
exhibit histopathological features of invasive carcinoma, but have the potential, 
over time and in response to risk factors, to develop into overt malignancy.  
Commonly described premalignant lesions of the oral cavity include 
leukoplakia, erythroplakia and submucous fibrosis.   Each has a different 
likelihood of developing into overt carcinoma.    The malignant potential of 
other lesions like oral lichen planus is yet to be established beyond doubt.   The 
risk factors implicated in the development of premalignant lesions are broadly 
the same as those for invasive squamous cell carcinoma.   
 
Leukoplakia is defined as the presence of a white plaque or patch that cannot be 
classified, either on clinical or histopathological examination, as any other 
characterized disease process.   On histopathology, leukoplakic patches show 
hyperkeratosis, dysplasia or carcinoma in situ.  A small percentage of these 
patches (3.1%)  can contain invasive squamous cell carcinoma, which had been 
mistaken as a benign premalignant process, as was reported by Waldron et al in 
their description of a large series comprising 3256 specimens (23).  Leukoplakia 
occurs more commonly in middle aged to older males and is frequently noted 
over the buccal and gingival mucosa.  Variants described include nodular 
leukoplakia, speckled leukoplakia (with interspersed patches of erythroplakia) 
and proliferative verrucous leukoplakia,  the last of which is associated with a 
higher risk of progression to invasive carcinoma (noted in upto 70%) (24).  The 
malignant potential of leukoplakia is reported to range from 15.6 to 39.2%.   
Lee and colleagues noted among a cohort of patient  patients with leukoplakia, 
after a median 7 year follow up, that the incidence of invasive carcinoma was 
31.4%, with an annual incidence of 5.7% (25).   Important considerations in the 
management of leukoplakia include biopsy of suspicious lesions to uncover 
masquerading malignancy and the use of beta carotenes and 13 – cis retinoic 
acid, which have been shown to induce regression of these lesions, though 
conclusive trials are still underway. 
 
In appearance, erythroplakia is the erythematous counterpart of leukoplakia and 
is manifested as velvety, red lesions that are usually discrete.  It is important to 
distinguish erythroplakia from inflammatory conditions of the oral cavity, 
which can present in a similar fashion.   Though usually asymptomatic, few 
patients can present with a burning sensation.  Erythroplakia is commonly noted 
in older males, on the floor of the mouth or the lateral border of the tongue.  
Though less commonly prevalent in comparison to leukoplakia  (0.1 – 0.6 %   
vs 10.3%), it is more likely to be dysplastic.  Histopathological examination of a 
series comprising 65 specimens showed dysplasia in all cases, with half 
demonstrating invasive carcinoma (26). 
 Submucous fibrosis is a condition which involves extensive inflammation and 
fibrosis in the lamina propria and deeper tissues, predominantly affecting the 
buccal mucosa. This causes trismus, which in addition to affecting the quality of 
life by limiting oral intake, can also interfere with complete examination and 
biopsy of the oral cavity, impeding the diagnosis of malignancy.  The 
development of submucous fibrosis is strongly linked to the use of various 
forms of smokless tobacco, mentioned earlier.  A malignant transformation rate 
of 17% has been reported.   
 
Pathogenesis: 
Our current understanding of the pathogenesis of head and neck malignancies 
owes it’s origin to the contribution made by Slaughter, when he proposed his 
theory of field cancerization.  Following histopathological examination of  738 
resected specimens containing malignancies of the oral cavity or pharynx,  he 
made the observation that there were multiple areas exhibiting various degrees 
of dysplasia in the macroscopically normal tissues adjoining the tumour  (27)   
 
Further work carried out along these lines involved follow up of dysplastic 
lesions to observe how many of them progressed to invasive carcinonma, and 
comparison of the molecular profiles of synchronously present dysplastic and 
malignant foci.  A malignant transformation rate of 51% (variably reported as 
15 – 30% by other investigators) was noted in one study which included 97 
dysplastic lesions followed up for a mean duration of 30 months.  It was 
additionally noted on subgroup analysis that the potential for malignant 
transformation was directly proportional to the degree of dysplasia (28).  It was 
also observed on molecular analysis that the genetic alterations noted in 
synchronously present dysplastic and malignant foci were not always 
concordant (29).   These findings led to some important conclusions – that 
dysplasia and malignancy had similar causative factors and that there was a 
clear progression of certain dysplastic lesions to overt malignancy.   It was also 
demonstrated that adjacent clinically normal tissue was preconditioned as a 
result of field cancerization and had the potential to later develop second 
primary malignancies in response to a different set of initiating events, as 
evidenced by molecularly discordant clones. 
 
From these findings evolved our understanding that the development of invasive 
carcinoma from premalignant lesions is a multistep process, as described in 
Vogelstein’s hypothesis for colonic cancer.  It involves mutations at multiple 
steps, affecting genes involved in mitosis, cell cycle regulation, cell to cell 
adhesion, cell signaling pathways, apoptosis and DNA repairs.   Progressive 
accumulation of these mutations due to different initiating events, results in the 
development of invasive carcinoma from premalignant and dysplastic lesions.    
 
Implicated genes that are involved in mitogenesis and cell signaling pathways 
include epidermal growth factor receptor (EGFR), transforming growth factor – 
alpha (TGF-alpha), HRAS (of the Ras family) and HER2 gene (30), (31), (32).   
Cell cycle control factors disrupted include cyclin D1 (overexpression) with 
inactivation of p53, p16 and p14 foci (33), (34), (35) .  Mutations of the doc 1 
(deleted in oral cancer) gene and genes associated with E – cadherin and matrix 
metalloproteinases cause disruption of intercellular adhesion and differentiation 
(36), (37), (38) .  Upregulation of Bcl-2 (B – cell leukaemia - 2) and Bcl- xL, 
two genes involved in the antiapoptotic pathways are also noted in head and 
neck malignancies (39).  Observation of these mutations associated with 
squamous cell carcinoma of the head and neck is of both prognostic and 
therapeutic significance.  
 
Pathology: 
The most common histological type is squamous cell carcinoma, which 
accounts for 90 – 95% of all malignancies of the oral cavity.  These 
malignancies are further classified on the basis of differentiation into well 
differentiated (> 75% keratinisation), moderately differentiated (25% - 75% 
kertininzation) and poorly differentiated (<25% keratininzation) types.  
 
Presentation: 
Patients commonly present with a growth or ulcer, corresponding to the 
exophytic or ulcerative forms of the disease.  These lesions may be associated 
with pain and occasionally with bleeding as well.  Carcinoma of the alveolus 
can present as loosening of the teeth.  On examination, in addition to exophytic 
or ulcerative lesions, areas of induration, seen in infiltrative forms can be 
present.  Premalignant lesions may also be seen.  Depending on the site, 
advanced malignancies may present with trismus, difficulty in speech, 
swallowing or protrusion of the tongue, skin involvement, cervical 
lymphadenopathy and neuropathy involving the hypoglossal, marginal 
mandibular and inferior alveolar nerves. 
 
Diagnosis and staging: 
Given the accessibility of the oral cavity, diagnosis is usually straightforward 
and is established by complete physical examination, followed by 
histopathological examination of wedge biopsies from the edge of suspicious 
lesions.    Fine needle aspiration cytology comes into play in the presence of 
palpable neck nodes, either in isolation or in conjunction with an oral lesion. 
 
The utility of imaging modalities – CT or MRI lies mainly in the more accurate 
identification of the extent of disease - particularly in infiltrative lesions, 
commonly seen in the tongue and to determine invasion of cortical bone.  It is 
also used in the identification of cervical nodal metastasis, detection of second 
primaries and distant metastatic disease.  While CT scan is superior for 
detection of infiltration of bone, MRI scanning provides better soft tissue 
resolution and is preferred for visualization of perineural invasion, intracranial 
extension and accurate delineation of tongue tumours.  The role of PET CT scan 
is limited to the detection of metastasis and occult primary malignancy in 
patients presenting with cervical lymph node metastasis. NPL scopy 
(nasopharyngolaryngoscopy) is done routinely in some centres for detection of 
second primary malignancies.  
 
Oral malignancies are most commonly staged according to the widely accepted 
AJCC (American Joint Committee for Cancer) classification, as mentioned in 
the 7
th
 edition of their handbook, which is as follows: 
T1 - < 2 cm 
T2 - 2–4 cm 
T3 - > 4 cm 
T4a – Lip - through cortical bone, inferior alveolar nerve, floor of mouth, skin 
- Oral cavity - through cortical bone, deep/ extrinsic muscle of tongue, 
maxillary sinus, skin of face 
T4b - Masticator space, pterygoid plates, skull base, encasing internal carotid 
artery 
 
N1 - Ipsilateral single < 3 cm 
N2 (a) - Ipsilateral single 3–6 cm 
      (b) - Ipsilateral multiple < 6 cm 
      (c) - Bilateral, contralateral < 6 cm 
N3 - > 6 cm 
 
M0 – No distant metastasis 
M1 – Distant metastasis present 
 
Stage 0 - Tis  N0  M0 
Stage I  - T1  N0  M0 
Stage II - T2  N0  M0 
Stage III - T3  N0  M0 
      T1, T2, T3  N1  M0 
Stage IVA - T1, T2, T3  N2  M0 
         T4a  N0, N1, N2  M0 
Stage IVB - Any T  N3  M0 
                     T4b  Any N  M0 
Stage IVC - Any T  Any N  M1 
 
Treatment : 
Current treatment protocols as defined by the NCCN guidelines recommend that 
for early stage tumours (stage I, II), either radiotherapy or surgery can be 
offered as curative modalities, though surgery is  usually preferred in most 
centres, as radiation can thus be reserved for recurrences, or in case of adverse 
prognostic factors on final histopathology. 
 
 In advanced stages, namely stages III and IVA, combined surgery and radiation 
is advised.   Radiation protocol includes 66 – 74 Gy administered as 5 fractions 
per week according to the conventional schedule.  Intensity modulated radiation 
therapy is preferred.  Adjuvant therapy in cases where the surgical resection 
margin is involved with tumour includes chemotherapy in addition to radiation.  
Chemotherapeutic agents commonly used include cisplatin, 5 fluorouracil and 
drugs belonging to the taxane group. 
 Prognosis: 
 As can be expected, the prognosis, specifically local recurrence and five year 
survival rates are progressively worse in direct proportion to the stage of the 
disease.   On surveying records of patients with oral cancer from 1996 – 2003, 
the SEER program calculated 5 year survival to be 82.8%, 51.8% and 27.8% for 
patients with local, regional and distant disease respectively.   
 
Adverse prognostic factors:   
Adverse prognostic factors that dictate the addition of chemoradiation include 
involved surgical resection margins (mucosal, soft tissue and bone) and 
extracapsular nodal spread of disease.  Other established indications for 
radiation include N2 or N3 disease, pT3, pT4 disease, perineural, vascular or 
lymphatic invasion and positive level 4 or level 5 nodes. 
Apart from these factors, it has also been proposed that the pattern of invasion 
of the tumour front seen on histology may have an impact on prognosis.  Spiro 
et al described 4 patterns of invasion as follows; Grade 1––invasion in a broad 
“pushing” front with well-delineated border; Grade 2––invasion at the 
advancing edge in the form of  solid cords, bands or strands; Grade 3––invasion 
in small groups or cords of infiltrating cells; Grade 4––marked cellular 
dissociation in small groups and/or single cells (40).  The latter two patterns 
were associated with poor prognosis.  On the basis of this, a histological 
assessment score (combining pattern of invasion, lymphocytic response and 
perineural invasion) for treatment and prognosis has been developed (41). 
Apart from patients with close or involved margins, it was also noted that 16 – 
32% of patients with negative resection margins also developed local 
recurrence, with a corresponding decrease in survival (3),(2).  It was hence 
hypothesized that tissue that appears phenotypically normal (on histopathology) 
may harbour genotypic abnormalities which may predict local recurrence, 
causing an impact on treatment and prognosis.  Using molecular markers, it was 
noted that these margins exhibited multiple mutations of various genetic loci (as 
mentioned earlier) particularly those coding for p53, p16 and eIF4e (a 
translation factor) (42), (43) .  On further evaluation, it was found that apart 
from being a more sensitive tool for the detection of malignancy, these markers 
were also found to be predictive of recurrence and survival.  However, trials 
including molecular markers in the treatment and prognosis of oral cancer are 
still underway and their routine use is not a part of standard clinical practice yet. 
 
Challenges in management: 
Preservation of function: 
There are specific challenges involved, peculiar to the management of 
malignancies of the oral cavity.  The small area, combined with its functional 
importance in terms of speech and swallowing, are a particular test to the skill 
of a reconstructive surgeon.  While oncological principles of resection cannot be 
compromised, mucosal continuity of the oral cavity has to be ensured to permit 
oral feeding.    
 
Reconstruction: 
In those patients who present with advanced stages of the disease, resection 
often results in a defect in the overlying skin as well, which also needs to be 
addressed.   Additionally, the cosmetic outcome of these procedures cannot be 
ignored.   For the above mentioned reasons, a microvascular free tissue transfer 
would be the ideal procedure for reconstruction of large defects, however the 
expertise and expense involved is often prohibitive.   As these patients are 
generally nutritionally compromised, wound healing is not optimal.  In patients 
undergoing operation for recurrence, prior radiation worsens wound healing, 
increasing the chances of flap reated complications.  Flap failure, infection or 
necrosis can result in an orocutanous fistula which, besides delaying initiation 
of oral nutrition, prolonging hospital stay and delaying rehabilitation, may 
require additional corrective procedures.  
Local and regional recurrence: 
Recurrence following curative therapy is another complication frequently 
encountered in the management of oral cancery.  Recurrence can take the form 
of either local recurrence at the resection site or region recurrence in the neck.  
Local recurrence rates have been variably reported as  10 - 16%, with 
locoregional recurrence upto 21%  (44), (45) depending on the mean follow up 
period.  Important predictors of recurrence include close or involved surgical 
resection margins and pattern of invasion of the tumour front.  It has also been 
suggested that neodjuvant chemotherapy may play a role in recurrence, as the 
deep margin can be difficult to judge and may lead to inadequate tumour 
clearance (44).  Locoregional recurrence is clearly associated with reduced 5 
year survival rates and carries an overall poor prognosis.   Three year cancer 
specific survival rates of  27.2 % – 64.3 % have been reported, depending on the 
clinical stage of the recurrence and the expression of molecular markers, 
particularly EGFR (46). 
Synchronous, second primary tumours: 
The observation that tumour biology is king is decidedly apparent in oral 
malignancies where, as a result of field cancerization, the incidence of second 
primary tumours is increased.  A large retrospective study by Day et al noted 
that in head and neck cancers, second primaries developed at the rate of 3.7% 
per year, with a relative risk nearing 20 for oral cavity cancers at 3 years 
following treatment (47).  Rogers et al noted a second primary rate of 7% (45).    
The incidence rate varies according to definition, however most investigators 
prefer to use the criteria set down by Warren and Gates in 1932 (76).  Second 
primaries can be either synchronous (detected within 6 months of diagnosis of 
the primary tumour ) or metachronous (detected after 6 months from diagnosis 
of the primary tumour).  They are distinguished from the primary tumour by the 
presence of 2 cm of normal intervening mucosa and a time interval of 3 years.  
These definitions have, however, been called into question following the advent 
of molecular typing.  Newer concepts include second field tumours (as opposed 
to second primary tumours) and premalignant cell migration, which may in 
future have a therapeutic and prognostic impact (48). 
   
Importance of negative surgical resection margins: 
It has been clearly demonstrated that both close and involved margins are 
associated with higher rates of local recurrence and poorer 5 year survival rates.  
Loree et al noted local recurrence rates of 36% in patients with close or 
involved margins, as opposed to 18% in those with pathologically adequate 
margins.    On follow up, they found that the 5 year survival rate in the former 
group was 52%, compared to 60% noted in those with adequate margins  (2).  
Binahmed et al reported that the 5 year survival rates in patients with clear, 
close and positive margins were 69%, 58% and 38% (4) .  Both these findings 
were statistically significant.  This emphasized the importance of obtaining 
adequate surgical resection margins.   
 
In addition, of all the identified adverse prognostic factors, the surgical 
resection margin was the only alterable factor.  As per the NCCN guidelines, 
the presence of close margins (invasive carcinoma < 4cm from the edge of the 
specimen) warrants the addition of radiation and positive margins (invasive 
carcinoma at the edge of the resection specimen) mandates either re- excision or 
additional chemoradiation.  It has also been noted that though recurrence rates 
decreased following adjuvant radiation therapy, it still didn’t compare to those 
who had adequate margins initially.  There was no significant improvement in 5 
year survival following adjuvant radiotherapy for management of positive 
resection margins (2). 
 
The worldwide incidence of close and involved margins varied.  In order to 
assess the magnitude of the problem in our institution in comparison with 
international statistics, our institutional records of 50 consecutive patients 
undergoing curative resection for malignancies of the oral cavity prior to June 
2011 were reviewed.  It was found that 34% of our patients had involved 
margins, in contrast to 32% in Glasgow, 22% in Manitoba and 11% in New 
York.  The incidence of close margins was 44%, compared to a similar figure 
from Manitoba and 21% from New York (2), (49), (5).  Review of international 
literature does not show a consensus regarding the definition of involved or 
positive margins.  In the series in our institution and Manitoba, involved 
margins referred to the presence of invasive carcinoma at the resection margin.  
The series from New York included patients with dysplasia at the surgical 
margins as well, while the series from Glasgow, the involved margins group 
consisted exclusively of patients with dysplasia at the resection margins.   
 
Methods explored to address the problem: 
Various options have been explored to aid achieving negative surgical resection 
margins.  They include pre operative measures such as imaging in addition to 
clinical examination, for better visualization  of  the extent of the tumour and 
intra operative measures, including the use of vital stains, optical spectroscopy, 
frozen section examination of the margins and increasing the width of 
surrounding normal tissue excised.    
 
Increasing distance of normal tissue to be excised: 
The adequate amount of normal tissue that is required to be excised 
circumferentially surrounding the tumour is controversial.  A retrospective 
study comparing the distance of clear surgical margins with 5 year survival by 
Nason et al noted significantly improved 5 year survival rates as the distance of 
normal tissue increased.  They concluded that in their study cohort, which 
included various groups of patients - from involved margins upto 5 mm tumour 
free margins - each additional millimetre of tumour free tissue contributed to 
increased five year survival (49).  The optimum tumour free margin taken 
routinely in our centre was 1 cm.  This was corroborated by McMahon et all, 
who concluded that beyond 1cm macroscopic margin, there was no additional 
survival benefit.  They suggested that inadequate histopathological margins and 
recurrence in these patients was a result of poor tumour biology, rather than 
inadequate resection (50).    
 
However, there is notable discordance between the size of the resection 
specimen in situ and on histopathological examinaiton.  Studies in canine 
models showed mean shrinkage of 30.7% for lingual mucosa and 47.3 % for 
buccal mucosa, with maximum shrinkage following resection and additional  
shrinkage following fixation in formalin (36).  Beaumont and  Haines noted a 
46% reduction in longitudinal diameter with a mean reduction of 4.82 mm (77). 
They also concluded that shrinkage occurred mostly after resection, with 
formalin fixation contributing to 30% or less of the overall shrinkage.  Current 
NCCN guidelines recommend excision of 1.5 – 2 cm of normal tissue 
circumferentially around grossly malignant tissue. 
 
Intraoperative frozen sections: 
A large retrospective review from Mayo clinic including 24,880 pathology 
reports from general surgery specimens, reported a diagnostic accuracy rate of 
97.8% for intraoperative frozen sections (52).   Considering head and neck 
malignancy specimens alone,  a similar accuracy rate (98.3%) with  a sensitivity 
and specificity rate of 88.8% and 98.9% has been noted (53).    It was noted that 
in approximately 67% of patients,  resection margins were adequate using 
clinical examination alone (54).  Additionally, though high sensitivity and 
specificity rates have been noted, the improvement in overall outcome in terms 
of local recurrence and survival is yet to be proved beyond doubt.  It was noted 
that in approximately 67% of patients, resection margins were adequate using 
clinical examination alone. 
  
Optical spectroscopy: 
Spectroscopy is the study of the interaction between matter and radiated energy.  
Fluorescence spectroscopy analyzes the fluorescence from a particular sample.  
The property of certain cellular and extracellular components (endogenous 
fluorophores) - notably mitochondria, lysosomes, collagen and elastin- to emit 
absorbed light when excited by radiation of certain wavelengths is called 
autofluorescence, and is a property of normal tissue.  Changes in cellular 
components and extracellular matrix by a malignant process leads to alterations 
in the endogenous fluorophore concentration and distribution.  This is manifest 
as a loss of fluorescence, or variation in the intensity of autofluorescence, which 
can be measured by various devices and can be indicative of neoplastic 
transformation (55), (56).  Compared to direct visualization of autofluorescence, 
which is subjective and investigator dependent, analysis of digital fluorescence 
images yields more reliable results (57).  Loss of autofluorescence has also been 
used intraoperatively to identify the extent of tumour and to direct the  margin 
of resection (58).   
 
Diffuse reflectance spectroscopy is based on the principle that different cellular 
and extracellular components have distinct refractive indices and tend to scatter 
light differently.  Hence, when light of a certain wavelength is incident on 
tissue, different reflective or scatter spectra are noted depending on the 
composition of the tissue.  This scatter spectrum can be analyzed by various 
fibreoptic probes and other devices.   Given the changes in tissue composition 
associated with neoplasia, malignant tissue can be differentiated from normal 
tissue by various types of  reflection spectroscopy.   Analysis of scatter spectra 
using white light, ultraviolet light and the interaction of gold impregnated 
nanoparticles have been described  to better delineate malignancies in the oral 
cavity (59), (60) .                                              
 
Vital stains – Lugol’s iodine: 
To identify malignancy, vital stains commonly used in clinical practice include 
toludine blue and Lugol’s iodine.   The sensitivity and specificity of toluidine 
blue was noted to be 0.925 and 0.632, while that of Lugol’s iodine was 0.875 
and 0.842,  respectively (61).    Due to low specificity and limited utility in 
dysplasia, toludine blue is not preferred (62), (63).  
 
Lugol’s iodine is a combination of iodine (I2), potassium iodide (KI) and 
distilled water, which in various proportions forms the different percentages of 
the solution available (10%, 5%, 3%, 1.25%).  5% Lugol’s iodine contains 5 g 
of iodine mixed with 10 g potassium iodide and 85 ml distilled water.  The total 
iodine content of this solution is 150 mg/ml.  It penetrates living tissue and 
binds to glycogen found in superficial epithelial cells, staining normal tissue 
mahogany brown or black.   Due to increased utilization of glycogen by 
malignant tissue (Warburg effect) associated with unchecked cellular 
proliferation, malignant cells contain less glycogen and therefore appear as 
ayellow, pale, unstained lesion (64), (65).  Based on this principle, malignant or 
dysplastic tissue can be identified from normal tissue.   
 
Lugol’s iodine was primarily used in the treatment of toxic goitre.  As a vital 
dye, it gained widespread popularity as the Schiller’s test, to identify dysplastic 
and malignant lesions in the cervix.  It’s use in the upper aerodigestive tract 
began with identification of dysplastic lesions in the oesophagus during 
endoscopy (66).  This was later employed in the oral cavity, as a simple test for 
diagnosis of suspicious lesions and for taking directed biopsies.    It was also 
shown in one study that different shades of discolouration after application of 
Lugol’s iodine was associated significantly with the varying degrees of 
dysplasia.  Based on this observation, the investigators hypothesized that it was 
possible to develop a colorimetric scale correlating with histopathology, that 
would enable macroscopic discrimination of the various degrees of dysplasia by 
comparing the shade of the unstained lesion with a colour scale (67) .   
 
Apart from phenotypical studies, genotypical studies involving measurement of 
p53, PCNA (proliferating cell nuclear antigen) levels and telomerase activity, 
which are associated with malignancy in tissues, also revealed good correlation 
between Lugol’s unstained areas and the presence of malignancy (68), (69) .  
Later studies were directed towards the use of Lugol’s iodine to better identify 
margins.    Kurita et al compared the distance between the boundary of the 
tumour noted following the application of Lugol’s iodine, with the location of 
the proliferative tumour front on final histopathology.  They noted a mean 
difference of 0.81 mm + 0.64 mm (mean + standard deviation), showing that the 
margin of the lesion on examination with Lugol’s iodine correlated well with 
the histopathological tumour front (70).  
 The wide availability, ease of use, rare occurrence of side effects and modest 
cost of Lugol’s iodine  makes it a promising option to employ, in a bid to reduce 
the incidence of close or positive surgical resection margins.  However, Lugol’s 
iodine cannot be used in keratinized epithelial surfaces and the normal 
epithelium in these tissues contains only small amounts of glycogen.  Hence, in 
these regions, normal tissue also appears unstained and cannot be differentiated 
from malignant tissue.   
 
Other methods: 
Other methods including brush cytology, improved imaging with MRI for better 
determination of the extent of the lesion preoperatively have also been used 
with varying success. 
 
 
 
  
 
 
 
 
Aims and Objectives 
 
 
 
 
 
 
 
 
 
Aim: 
To study the  utility of Lugol’s iodine in achieving tumour free surgical margins 
in squamous cell carcinoma of the oral cavity. 
 
Objectives: 
(1)  To determine whether the use of lugol’s iodine resulted in reduced 
incidence of involved or close surgical margins, in squamous cell 
carcinoma of the oral cavity. 
 
(2)  To determine whether the use of Lugol’s iodine enabled the surgeon to 
better visualize the tumour extent compared to clinical examination alone. 
 
(3)  To study the staining patterns observed following local application of 
Lugol’s iodine in squamous cell carcinoma of the oral cavity. 
 
(4)  To look for association between the various staining patterns and the 
incidence of involved and close resection margins on final 
histopathology. 
 
 
  
 
 
 
 
 
 
 
 
 
Materials and Methods 
 
 
 
 
 
 
 
Following approval by the institutional review board, after taking informed 
consent, all consecutive eligible patients operated from 15.09.12 to 15.10.13 (13 
months) were enrolled in the study.  No method of randomization or blinding 
was used. 
Inclusion criteria: 
(1)  Biopsy proven squamous cell carcinoma. 
(2)  Primary malignancies of the alveolus, buccal mucosa, anterior tongue 
and floor of  mouth. 
(3)  Resectable tumours. 
(4)  Age > 18 years. 
Exclusion criteria: 
(1)  Known allergy to iodine. 
(2)  Severe trismus noted preoperatively. 
(3)  Pregnancy. 
Procedure: 
 Intra-operatively, on examination under anesthesia, the extent of the 
tumour on clinical examination was determined and marked.   The 
proposed boundary of resection including a 1 cm circumferential margin 
of normal tissue was marked using diathermy. 
 
 Mucus secretions were removed by irrigating the oral cavity with 30 ml 
of   5% carbocisteine syrup, left for  1 minute. 
  The entire oral cavity was irrigated with 1.25% Lugol’s iodine taken in a 
10ml syringe. 
 Excess Lugol’s iodine was removed using suction. 
  Irrigation with Lugol’s iodine was repeated until the mucosa distant to 
the malignancy stained dark brown. 
 The adequacy and pattern of staining with  Lugol’s iodine was noted.  
 The extent of the tumour following the application of Lugol’s iodine was 
compared for any discordance and the resection boundary was revised 
where deemed appropriate. 
   Resection was carried out according to the surgeon’s discretion,  by 
either 
-  following the initial plan, guided by clinical margin alone, 
-  increasing the resected area as indicated following the use of Lugol’s 
iodine, or  
- additional stripping of the mucosa  in cases where there were large areas 
of abnormal mucosa indicated by Lugol’s iodine, but not identified on 
clinical examination . 
 The resected specimen was oriented, fixed in formalin and sent for       
histopathological examination. 
The primary outcome measured was the incidence of close and involved 
margins in this group of patients, designated group B.  The margin status in 
these patients was noted and compared with a retrospective cohort of similar 
patients (60 patients operated from 15.05.10 – 15.06.11), designated group A 
 
 The results were tabulated and subject to statistical analysis.  Pearson’s chi 
square test/ Fischer’s exact  test was used as applicable, to identify significant 
association. 
 
 
 
 
        
 
 
 
 
 
Procedure and interpretation of staining with Lugol’s iodine 
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Results and Analysis 
 
 
 
 
 
A  total of 90 patients with squamous cell carcinoma of the oral cavity 
underwent curative resection from 15.09.12. to 15.10.13.  Of these, 86 patients 
fulfilled the requisite eligibility criteria.  Consent could not be obtained from 24  
of these patients, hence 62 patient underwent the abovementioned procedure.  
Of these, adequate data was unavailable for 32 patients, hence a total of 30 
patients were finally included in the study for analysis.  
 
Patterns of staining: 
 
 Pattern 1:  The margins on clinical examination and following staining 
with Lugol’s iodine were concordant. 
 Pattern 2:  The margins on clinical examination and following staining 
with Lugol’s iodine were discordant.  The Lugol’s margin exceeded the 
clinical margin in a particular direction. 
 Pattern 3: The margins on clinical examination and following staining 
with Lugol’s iodine were vastly discordant .  The Lugol’s margin greatly 
exceeded the clinical margin in three or more directions, resulting in a 
diffuse unstained lesion. 
 
 
 Pattern 1 – Lugol’s margin = clinincal margin 
Pattern 2 – Lugol’s margin > clinical margin in a particular direction 
Pattern 3 – Lugol’s margin >> clinical margin (diffuse unstained 
lesion) 
Fig 2.1 – Patterns of staining noted following application of Lugol’s iodine 
Demographic profile of patients 
 
Variable 15.05.10- 15.06.11 
  
n = 60 (GroupA) 
15.09.12- 15.10.13. 
 
n = 30 (Group B) 
 
Age 
<40 7 (12%) 6 (20%) 
40-60 33 (55%) 15 (50%) 
>60 20 (33%) 9 (30%) 
Gender Male 43 (72%) 16 (53%) 
Female 17 (28%) 14 (47%) 
Site Alveolus 9 (15%) 3 (10%) 
Buccal mucosa 19 (32%) 5 (17%)  
Tongue 26 (43%) 20 (67%) 
Others 6 (10%) 2 (6%) 
Smoking Yes 14 (23%) 5 (17%) 
No 46 (77%) 25 (83%) 
Alcohol Yes 11 (18%) 3 (10%) 
No 49 (82%) 27 (90%) 
Paan Yes 33 (55%) 13 (43%) 
No 27 (45%) 17 (57%) 
 
Variable 15.05.10-15.06.11  
 
n = 60 (Group A) 
15.09.12-15.10.13  
 
n = 30 (Group B) 
Prior operation 
at the same site 
Yes 8 (13%) 1 (3%) 
No 52 (87%) 29 (97%) 
Prior 
chemotherapy 
Yes 12 (20%) 6 (20%) 
No 48 (80%) 24 (80%) 
Prior radiation 
at same site 
Yes 3 (5%) 1 (3%) 
No 57 (95%) 29 (97%) 
Clinical T 
stage 
1 10 (17%) 6 (20%) 
2 19 (32%) 16 (53%) 
3 9 (15%) 2 (7%) 
4 20 (33%) 6 (20%) 
x 2 (3%) 0 (0%) 
Clinical N 
stage 
0 20 (34%) 16 (54%) 
1 26 (43%) 7 (23%) 
2 14 (23%) 7 (23%) 
Clinical TNM 
stage 
 
I 8 (13%) 5 (17%) 
II 7 (12%) 9 (30%) 
III 17 (28%) 7 (23%) 
IV 26 (44%) 9 (30%) 
Indeterminate 2 (3%) 0 (0%) 
         
Variable 15.05.10-15.06.11  
 
n = 60 (Group A) 
15.09.12-15.10.13  
 
n = 30 (Group B) 
Pathological T 
stage 
1 25 (42%) 15 (50%) 
2 12 (20%) 10 (33%) 
3 4 (7%) 2 (7%) 
4 19 (31%) 3 (10%) 
Pathological N 
stage 
0 36 (60%) 19 (64%) 
1 7 (12%) 4 (13%) 
2 11 (18%) 4 (13%) 
3 0 (0%) 1 (3%) 
x 6 (10%) 2 (7%) 
Differentiation Well 25 (42%) 7 (23%) 
Moderately 32 (53%) 22 (74%) 
Poorly 3 (5%) 1 (3%) 
Reconstruction Primary 
closure 
25 (42%) 12 (40%) 
Minor 
reconstructive 
procedure 
6 (10%) 1 (3%) 
Major 
rotational flap 
18 (30%) 14 (47%) 
Free tissue 
transfer flap 
11 (18%) 3 (10%) 
 
  
Approximately half the patients fell in the 40 – 60 age group.  A greater 
proportion was male patients was noted in group A.  The most common sites of 
malignancy were the tongue, followed by the buccal mucosa.  Only 20 % of 
patients gave history of smoking .  A similar number consumed alcohol.  The 
most common risk factor  was chewing paan, which was noted in half the 
population.  20% of patients underwent neoadjuvant chemotherapy.  
Approximately 10% underwent prior operation at the same site, while nearly 
5% underwent prior radiation.   
In group A, 72% of patients presented with advanced disease (stage III, IV) as 
opposed to 53% in group B.  The most common clinical T stages were T2 and 
T4.  Most patients  had clinically node positive disease.  Histopathological 
examination showed 62% of patients had T1, T2 disease in group A, with no 
cervical nodal metastasis in 60%  of the population.  A higher proportion of 
early pathological T lesions were noted in group B.  Most tumours were 
moderately differentiated.  The most common method of reconstruction 
employed was a rotational flap.  A higher proportion of rotational flaps, 
compared to free tissue transfer flaps were used in group B.  
The proposed reconstruction plan was not altered in any patients following the 
use of Lugol’s iodine.  No patients had known allergy to Lugol’s iodine and 
none had any side effects related to it’s use.  The average additional operating 
time due to the use of Lugol’s iodine was 10 minutes.   
Fig 2.2.Association between margin status and the use of Lugol’s iodine (by 
percentage) 
 
 
In the group where Lugol’s iodine was used, there was a significant decrease in 
the incidence of close and involved resection margins (17% and 6%  in group B 
as opposed to 37% and 38% in group A). p = 0.000 
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                                             Lugol’s study 
Fig 2.3.Did staining with Lugol’s iodine aid better visualization of the 
tumour (surgeon’s subjective assessment)? 
 
In 90% of patients, the tumour was better defined following application of 
Lugol’s iodine. 
Fig 2.4.Distribution of the patterns of staining following application of 
Lugol’s iodine  
 
Satisfactory staining ?  
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NoYes 
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No 
3 (10%) 
n = 30 
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Unclear 
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14 (47%) 
L> > C 
1 (3%) 
Fig 2.5.Was planned resection margin changed following the application of 
Lugol’s iodine? 
 
Fig. 2.6.Association between margin status and changing resection margin 
based on staining with Lugol’s iodine (pattern 2 only , n=14) 
Was 
resection 
changed 
according to 
lugol’s 
margin? 
Free margins Close 
margins 
Involved 
margins 
Total 
Yes 7 1 1 9 
No 4 1 0 5 
Total 11 2 1 14 
In half the population in group B (15 patients – patterns 2,3), the extent of the 
lesion as determined by Lugol’s iodine was larger compared to the margin on 
clinical examination.  The resection margin was extended in 9 patients (30% of 
group B), as guided by the Lugol’s margin.  All these patients showed the 
second pattern of staining, where the Lugol’s margin exceeded the clinical 
margin in a particular direction. 
Planned resection margin changed? 
Yes
No
No 
21 (70%) 
Yes 
9 (30%) 
n = 30 
Fig 2.7.Distribution of margin status in patients with staining pattern 
where Lugol’s = clinical margin (pattern 1) 
 
Fig. 2.8.Distribution of margin status in patients with staining pattern 
where Lugol’s margin > clinical margin in a particular direction (pattern 
2) 
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In both patterns 1 and 2 , a majority of patients (approximately 80%) had free 
margins on final histopathology. 
Fig 2.9.Distribution of margin status in patients with staining pattern 
where staining with Lugol’s iodine was unsatisfactory in identifying the 
lesion 
 
In the 3 patients in whom staining with Lugol’s iodine failed to delineate the 
lesion, resection was carried out according to the clinical margin.  Final 
histopathology did not show involved margins in any of these patients. 
 
In the 1 patient in whom Lugol’s margin far exceeded the clinical margin 
(pattern 3), resection was carried out as per the clinical margin and final 
histopathology showed free margins. 
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Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 In view of the high incidence, oral malignancies are of particular relevance in 
India.   The presence of invasive carcinoma at or within 5 mm of the resection 
margins, besides being a major determinant in further treatment and prognosis 
of the disease, is also one of the few modifiable factors associated with the 
disease.    
 
Besides the presence of invasive carcinoma at or close to resection margins, the 
presence of dysplasia has also been noted to have an adverse effect on 
prognosis.  Malignant transformation rates of 6% for mild dysplasia, 18% for 
moderate dysplasia and 39% for severe dysplasia have been reported (71).  A 
meta analysis investigating the rate of malignant transformation reported 10.3% 
for mild and moderate dysplasia, compared to 24.1% for severe dysplasia and 
carcinoma in situ (72).  Another factor to be borne in mind is that resection 
margins include mucosal, soft tissue and bony components.  In their series of 
301 patients including 70 patients with involved resection margin, Woolgar et al 
observed that mucosal margins were involved only in 11% of patients, as 
opposed to bony margin involvement in 14% and deep soft tissue margin 
involvement in 87% (6).  Hence, three dimensional clearance is essential.  
Additionally, the development of local recurrence inspite of adequate resection 
margins, even in early lesions indicates that phenotypically normal tissue may 
harbour mutations that can progress to dysplasia and overt carcinoma. 
 
 Of the different methods explored to address the problem of close and involved 
resection margins, most - including the use of frozen sections, MRI scanning 
and spectroscopy- significantly increase operating time or expenditure.  Lugol’s 
iodine holds particular appeal due to the wide availability, speed and ease of 
use, limited cost and few side effects.    Additionally, Lugol’s iodine has been 
shown to identify dysplasia (70) and has also been shown to correlate well with 
molecular markers of malignancy like telomerase and p53 alterations (68), (69). 
 
Though the use of Lugol’s iodine in the detection and diagnosis of oral 
malignancies has been well described, few studies report it’s utility in guiding 
resection and decreasing the incidence of close and involved resection margins.    
McMahon et al reported that it helped decrease the incidence of dysplasia at and 
close to resection margins, from  32% in a retrospective control group to4% in 
the Lugol’s study group (5).  A randomized control study of the same is in 
progress. 
 
Our institutional experience  showed a significant reduction in the incidence of 
close and involved margins (17 % and 6%) following the use of Lugol’s ioidine,  
compared to a retrospective cohort  (37% and 38%).   On comparing the clinical 
margin with the Lugol’s iodine margin, three patterns were noted, as described.   
The association between each of the different patterns and margin status was 
difficult to interpret, as the numbers in each category were few. 
 
 In 3 patients, the lesion was not clearly delineated.  All 3 were tongue lesions, 
where the lesion was small on inspection and the predominant portion of the 
lesion was palpable rather than visible.  This likely represents subepithelial 
disease, which cannot be identified by Lugol’s iodine.   
 
Lugol’s iodine was primarily useful in 7 patients (23%) showing pattern 2 
staining, in whom the resection was increased according to the Lugol’s iodine  
margin and resulted in free resection margins.  Lugol’s was also helpful in 
better defining the lesion in patients showing pattern 1 staining.  Though the 
extent of resection remained the same, the operative surgeons were of the 
opinion that the lesion showed up more distinctly following staining, thereby 
facilitating resection.  Additionally, staining with Lugol’s iodine resulted in an 
irregular lesion as opposed to a smooth contoured lesion, as generally marked 
on clinical examination.   Making allowance for this geographic pattern while 
deciding the resection margin may have improved completeness of resection.       
 
In  53% of the population in group B (16 patients – 12 showing pattern 1, 4 
showing pattern 2, 1 each showing pattern 3 and unsatisfactory staining with 
Lugol’s iodine), clinical examination alone was enough to ensure adequate 
margins.  This was comparable to similar data noted by Byers and other 
investigators in studies comparing the utility of clinical margin alone with the 
addition of frozen sections (54), (73).  .   
 
Lugol’s iodine failed to detect malignancy in 2 patients (7%), who had involved 
margins on histopathology.  Of these, 1 patient showed pattern 1 staining, where 
both clinical examination and Lugol’s iodine examination failed to accurately 
delineate the lesion.  In the second patient, the anterior extent  of resection was 
increased axxording to the Lugol’s margin (pattern 2),  however final 
histopathology showed involvement of the medial and lateral margins.  
 
 Lugol’s iodine cannot be used for improvement of soft tissue resection 
margins.  It cannot be used in heavily keratinized epithelium and is of limited 
utility in the delineation of  infiltrative lesions. 
Limitations: 
The prinicipal limitation of this study was the small number of patients 
available for final analysis, making determination of trends and their 
significance difficult.   Additionally, histopathological diagnosis of those areas 
discordant on clinical and Lugol’s examination was unavailable and resection 
was left to the surgeon’s discretion .  It was hence difficult to determine the 
strength of association between improvement in margin status and staining with 
Lugol’s iodine. 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Conclusion  
Conclusion: 
 
With appropriate patient selection, staining with Lugol’s iodine appears to be a 
promising method of obtaining tumour free resection margins in carcinoma of 
the oral cavity.  However, studies with a larger sample size and randomization 
are required to further establish it’s utility. 
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                                                 PROFORMA 
 
Date:   Name:                          H. No.: 
Age:   Sex:                                                       Study ID No.: 
Known history of iodine allergy: 
Smoking:        Alcohol:    Paan use: 
Previous treatment: 
If yes, when  - surgery              : 
- radiotherapy  : 
Premalignant/ inflammatory lesions: 
Anatomical site: 
Clinical stage: 
 
 
Surgeons subjective assessment: 
( Please circle either Y- yes or N – no) 
(1)   Was the staining with Lugol’s adequate, did it demarcate any      
       specific region to be malignant (as opposed to inadequate     
       staining with unclear, ill defined borders) – Y/ N 
(2)  Was the planned resection margin modified following the use of     
       Lugol’s iodine? – Y/ N 
      If no, please skip question 3. 
(3)  If yes -  (a) in how many directions (please circle one option)  -    
                           1/ 2/ 3/ 4 
 (b) which direction (please circle as many as indicated by 
      previous answer) – anterior/ posterior/ medial or  
      inferior/ lateral or superior 
(4)  Was the plan of reconstruction of the defect changed as a result  
       of a larger area being resected following the use of Lugol’s  
       iodine?  - Y/N 
(5)  What was the additional time added to the surgery as a result of  
       the use of Lugol’s iodine (approximately) ?     
(6)  Were there any adverse reactions noted following the use of  
       Lugol’s iodine 
       (a) immediately  - Y/N 
       (b) at the end of the surgery Y/N 
       (c) at the end of the patient’s hospital stay? Y/N  
       (if yes, please specify) 
(7)  Were there any new unstained areas, otherwise unidentified on  
       clinical examination? Y/N 
      If yes,(a)  how many such areas 
                (b) what was the location – in continuity with the tumour/   
                                                                 in different anatomical subsite 
(8)  Which scenario did the staining pattern fit into ?   1/ 2/ 3 
 
(9) Are there any other comments? 
 
 
                            Patient  information  sheet 
 
You are invited to participate in a study that researches the use of Lugol’s 
iodine in cancers of the mouth. 
Cancers in the interior of the mouth tend to occur repeatedly, inspite of 
treatment. Surgery for these cancers aims at complete removal of the cancer. In 
cases where the cancer is not removed completely by surgery, the chances of the 
cancer occurring again in the same place is higher. This leads to the requirement 
for additional treatment and increased risk of death. Various studies have shown 
that  Lugol’s iodine is useful in identifying and marking out areas of cancer. If 
the area to be removed during surgery is decided following marking using 
Lugol’s iodine instead of according to what is seen and felt to be the edge of the 
cancer, the chances of completely removing the cancer is greater. This will lead 
to decreased chances of the cancer returning in the same region, decreased need 
for further treatment in some cases and decreased risk of death. 
Lugol’s iodine is a solution containing potassium iodide and iodine. It is used in 
a variety of diseases and depending on the disease , it can be either ingested or 
used on the surface of the body. In this study, Lugol’s iodine is used as it can 
differentiate between cancerous and normal regions when applied on the surface 
of certain parts of the body. When used in this fashion, it has occasionally 
caused allergic reactions and ulcers. 
In this study, the procedure will be as follows. The surgeon will see and feel the 
cancer and mark out what is felt to be the limit of the cancer. 5% Carbocysteine 
syrup will be applied on the inner surface of the entire mouth. This will remove 
the saliva and secretions on the inner surface of the mouth. This will be 
followed by application of 1.25% Lugol’s iodine and normal saline alternately 
till the regions far away from the cancer turns dark brown or black. The area of 
the cancer will appear yellow. This colour difference is used to mark out the 
cancer from the surrounding normal tissues. The cancer is cut 1 centimetre 
away from the margin decided by the surgen as the edge of the cancer. A 
proforma is filled out based on observations made during the operation. The 
removed cancer will be sent for examination under a microscope. This will 
show whether any cancer cells have been left behind in the body. Comparing 
this report with the information in the proforma and records of our past patients, 
we can determine whether Lugol’s iodine served it’s purpose or not. 
In the rare case of unpleasant side effects caused by the drug, further treatment 
of the side effect including the expenses incurred for it will be managed by the 
treating unit. Participation is entirely voluntary and you can withdraw from the 
study at any time. Information obtained during this study will remain 
confidential. The decision to take part in the study or not will not influence any 
further treatment you receive at this hospital. 
  
CONSENT TO TAKE PART IN A CLINICAL TRIAL 
 
Study Title: The use of Lugol’s iodine in achieving surgical margins free from 
dysplasia and invasive carcinoma in squamous cell carcinoma of the oral cavity 
 
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
 
(Please tick boxes) 
Declare that I have read the information sheet provide to me regarding this 
study and have clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and 
that I am free to withdraw permission to continue to participate at any time 
without affecting my usual treatment or my legal rights [ ] 
I understand that I will receive free treatment for any study related injury or 
adverse event but I will not receive and other financial compensation [ ] 
I understand that the study staff and institutional ethics committee members will 
not need my permission to look at my health records even if I withdraw from 
the trial. I agree to this access [ ]  
I understand that my identity will not be revealed in any information released to 
third parties or published [ ]   
I voluntarily agree to take part in this study [ ] 
 
Name: 
Signature: 
Date: 
 
Name of witness: 
Relation to participant: 
 
 
 
  
 
 
  
SNO DATE FIELD1 FIELD2 NAME HNO HNO1 AGE SEX IALLERGY SM ALC PAAN PSX PCH PRT SITE CT CN REC MARGINS DIRINAD AIN PIN MIIN LAIN PT PN DIFF SATISF AS MARGIN AMOD PMOD MIMOD LSMOD DUE LUGOLS ADV PATTERN 
1 19 9 12 umarani 231347 f 6 2 2 2 2 1 2 1 2 1 4 2 5 1 2 2 2 1 1 4 3 3 1 2 0 2 2 2 2 2 1 2 1 
2 21 9 12 fuljan 237787 f 6 2 2 2 2 1 2 1 2 2 4 2 5 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 1 2 1 
3 3 10 12 raghupathi 895262 c 7 1 2 1 2 2 2 2 2 5 2 1 1 1 2 2 2 1 1 1 0 2 1 1 2 1 1 2 2 2 1 2 2 
4 17 10 12 vengatesan 237865 f 2 1 2 1 2 2 2 1 2 3 2 1 9 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 1 2 1 
5 7 12 12 karfu 281076 f 4 1 2 2 1 1 2 1 2 3 1 0 11 3 0 2 2 2 2 1 0 1 1 2 0 2 2 2 2 2 1 2 2 
6 19 12 12 parvadham 356110 f 6 2 2 2 2 1 2 2 2 3 2 2 1 3 0 2 2 2 2 2 2 2 1 1 2 2 1 1 2 2 1 2 2 
7 2 1 13 nirmala 285641 f 4 2 2 2 2 2 1 1 1 3 2 0 11 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 1 2 2 
8 4 1 13 sheikh 372065 f 3 1 2 2 2 1 2 2 2 3 3 0 1 3 0 2 2 2 2 2 0 1 1 2 0 2 2 2 2 2 2 2 2 
9 1 1 13 sundaraj 346406 f 4 1 2 2 1 1 2 2 2 3 2 0 11 2 1 2 2 2 1 3 0 2 2 2 0 2 2 2 2 2 1 2 4 
10 16 1 13 rose 220413 f 5 2 2 2 2 2 2 2 2 3 2 0 11 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 2 2 2 
11 27 3 13 mohammad 337931 f 4 1 2 1 2 2 2 2 2 3 2 1 1 2 1 2 2 1 2 3 1 2 1 2 0 2 2 2 2 2 2 2 1 
12 24 4 13 chengamma4 449653 f 4 2 2 2 2 1 2 2 2 2 4 1 5 2 1 2 1 2 2 4 0 2 1 1 2 1 2 1 2 2 1 2 2 
13 1 5 13 akilesh 454653 f 3 1 2 2 1 2 2 2 2 3 2 0 1 2 1 2 1 2 2 2 0 2 2 2 0 2 2 2 2 2 1 2 4 
14 29 5 13 sandhya 427236 f 5 2 2 2 2 2 2 2 2 3 2 0 11 3 0 2 2 2 2 1 2 2 2 2 0 2 2 2 2 2 1 2 4 
15 31 5 13 basanti 486633 f 6 2 2 2 2 1 2 2 2 3 2 0 11 3 0 2 2 2 2 2 1 2 1 2 0 2 2 2 2 2 1 2 3 
16 14 6 13 shilpi 489741 f 4 2 2 2 2 2 2 2 2 1 4 2 5 3 0 2 2 2 2 2 2 2 1 2 0 2 2 2 2 2 1 2 1 
17 19 6 13 unnikrishn 494788 f 3 1 2 2 2 2 2 2 2 3 3 0 7 3 0 2 2 2 2 1 0 2 1 1 1 1 2 2 2 2 1 2 2 
18 3 7 13 dilip 494718 f 6 2 2 2 2 2 2 2 2 3 1 0 1 3 0 2 2 2 2 1 4 2 1 1 1 2 1 2 2 2 1 2 2 
19 10 7 13 moidu 488070 f 5 1 2 1 2 2 2 2 2 3 2 0 1 3 0 2 2 2 2 1 1 1 1 2 0 2 2 2 2 2 1 2 1 
20 9 8 13 subramanya 726057 d 6 1 2 2 2 2 2 2 2 3 2 1 7 3 0 2 2 2 2 1 0 2 1 1 1 1 2 2 2 2 1 2 2 
21 23 8 13 samuel 47550 a 8 1 2 2 2 2 2 2 2 3 2 2 11 3 0 2 2 2 2 2 0 2 1 1 1 2 1 2 2 2 1 2 2 
22 7 11 12 vittal 231798 f 6 1 2 1 2 2 2 2 2 1 1 2 5 3 0 2 2 2 2 2 0 2 1 2 0 2 2 2 2 2 1 2 1 
23 12 10 12 reba 296228 f 4 2 2 2 2 1 2 2 2 3 1 0 1 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 1 2 1 
24 10 10 12 kalyani 253918 f 5 2 2 2 2 2 2 1 2 2 4 1 5 3 0 2 2 2 2 4 0 1 1 1 1 2 2 1 2 2 1 2 2 
25 2 10 13 vijaya 640922 f 5 2 2 2 2 1 2 2 2 2 4 2 2 3 0 2 2 2 2 2 2 2 1 2 0 2 2 2 2 2 1 2 1 
26 2 10 13 raghavan 659353 f 4 1 2 2 2 1 2 2 2 3 2 0 11 2 1 2 2 1 2 2 1 2 1 2 0 2 2 2 2 2 1 2 2 
27 2 10 13 sujoy 650735 f 3 1 2 2 2 1 2 2 2 3 1 0 1 3 0 2 2 2 2 1 4 1 1 2 0 2 2 2 2 2 1 2 1 
28 11 10 13 rajab 663420 f 3 1 2 2 2 2 2 2 2 5 2 1 1 3 0 2 2 2 2 2 0 2 1 2 0 2 2 2 2 2 1 2 1 
29 23 10 13 manickam 663172 f 5 2 2 2 2 2 2 2 2 3 1 0 1 3 0 2 2 2 2 1 0 1 1 2 0 2 2 2 2 2 1 2 1 
30 16 10 13 niranjan 668369 f 4 1 2 2 2 1 2 2 2 2 2 0 1 3 0 2 2 2 2 1 0 1 1 1 1 2 1 2 2 2 1 2 2 
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1 
19 9 12 umarani 231347 f 6 2 2 2 2 1 2 1 
2 1 4 2 5 1 2 2 2 1 1 4 3 3 1 2 0 2 2 2 2 2 1 2 1 
2 
21 9 12 fuljan 237787 f 6 2 2 2 2 1 2 1 
2 2 4 2 5 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 1 2 1 
3 
3 10 12 raghupathi 895262 c 7 1 2 1 2 2 2 2 
2 5 2 1 1 1 2 2 2 1 1 1 0 2 1 1 2 1 1 2 2 2 1 2 2 
4 
17 10 12 vengatesan 237865 f 2 1 2 1 2 2 2 1 
2 3 2 1 9 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 1 2 1 
5 
7 12 12 karfu 281076 f 4 1 2 2 1 1 2 1 
2 3 1 0 11 3 0 2 2 2 2 1 0 1 1 2 0 2 2 2 2 2 1 2 2 
6 
19 12 12 parvadham 356110 f 6 2 2 2 2 1 2 2 
2 3 2 2 1 3 0 2 2 2 2 2 2 2 1 1 2 2 1 1 2 2 1 2 2 
7 
2 1 13 nirmala 285641 f 4 2 2 2 2 2 1 1 
1 3 2 0 11 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 1 2 2 
8 
4 1 13 sheikh 372065 f 3 1 2 2 2 1 2 2 
2 3 3 0 1 3 0 2 2 2 2 2 0 1 1 2 0 2 2 2 2 2 2 2 2 
9 
1 1 13 sundaraj 346406 f 4 1 2 2 1 1 2 2 
2 3 2 0 11 2 1 2 2 2 1 3 0 2 2 2 0 2 2 2 2 2 1 2 4 
10 
16 1 13 rose 220413 f 5 2 2 2 2 2 2 2 
2 3 2 0 11 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 2 2 2 
11 
27 3 13 mohammad 337931 f 4 1 2 1 2 2 2 2 
2 3 2 1 1 2 1 2 2 1 2 3 1 2 1 2 0 2 2 2 2 2 2 2 1 
12 
24 4 13 chengamma4 449653 f 4 2 2 2 2 1 2 2 
2 2 4 1 5 2 1 2 1 2 2 4 0 2 1 1 2 1 2 1 2 2 1 2 2 
13 
1 5 13 akilesh 454653 f 3 1 2 2 1 2 2 2 
2 3 2 0 1 2 1 2 1 2 2 2 0 2 2 2 0 2 2 2 2 2 1 2 4 
14 
29 5 13 sandhya 427236 f 5 2 2 2 2 2 2 2 
2 3 2 0 11 3 0 2 2 2 2 1 2 2 2 2 0 2 2 2 2 2 1 2 4 
15 
31 5 13 basanti 486633 f 6 2 2 2 2 1 2 2 
2 3 2 0 11 3 0 2 2 2 2 2 1 2 1 2 0 2 2 2 2 2 1 2 3 
16 
14 6 13 shilpi 489741 f 4 2 2 2 2 2 2 2 
2 1 4 2 5 3 0 2 2 2 2 2 2 2 1 2 0 2 2 2 2 2 1 2 1 
17 
19 6 13 unnikrishn 494788 f 3 1 2 2 2 2 2 2 
2 3 3 0 7 3 0 2 2 2 2 1 0 2 1 1 1 1 2 2 2 2 1 2 2 
18 
3 7 13 dilip 494718 f 6 2 2 2 2 2 2 2 
2 3 1 0 1 3 0 2 2 2 2 1 4 2 1 1 1 2 1 2 2 2 1 2 2 
19 
10 7 13 moidu 488070 f 5 1 2 1 2 2 2 2 
2 3 2 0 1 3 0 2 2 2 2 1 1 1 1 2 0 2 2 2 2 2 1 2 1 
20 
9 8 13 subramanya 726057 d 6 1 2 2 2 2 2 2 
2 3 2 1 7 3 0 2 2 2 2 1 0 2 1 1 1 1 2 2 2 2 1 2 2 
21 
23 8 13 samuel 47550 a 8 1 2 2 2 2 2 2 
2 3 2 2 11 3 0 2 2 2 2 2 0 2 1 1 1 2 1 2 2 2 1 2 2 
22 
7 11 12 vittal 231798 f 6 1 2 1 2 2 2 2 
2 1 1 2 5 3 0 2 2 2 2 2 0 2 1 2 0 2 2 2 2 2 1 2 1 
23 
12 10 12 reba 296228 f 4 2 2 2 2 1 2 2 
2 3 1 0 1 3 0 2 2 2 2 1 0 2 1 2 0 2 2 2 2 2 1 2 1 
24 
10 10 12 kalyani 253918 f 5 2 2 2 2 2 2 1 
2 2 4 1 5 3 0 2 2 2 2 4 0 1 1 1 1 2 2 1 2 2 1 2 2 
25 
2 10 13 vijaya 640922 f 5 2 2 2 2 1 2 2 
2 2 4 2 2 3 0 2 2 2 2 2 2 2 1 2 0 2 2 2 2 2 1 2 1 
26 
2 10 13 raghavan 659353 f 4 1 2 2 2 1 2 2 
2 3 2 0 11 2 1 2 2 1 2 2 1 2 1 2 0 2 2 2 2 2 1 2 2 
27 
2 10 13 sujoy 650735 f 3 1 2 2 2 1 2 2 
2 3 1 0 1 3 0 2 2 2 2 1 4 1 1 2 0 2 2 2 2 2 1 2 1 
28 
11 10 13 rajab 663420 f 3 1 2 2 2 2 2 2 
2 5 2 1 1 3 0 2 2 2 2 2 0 2 1 2 0 2 2 2 2 2 1 2 1 
29 
23 10 13 manickam 663172 f 5 2 2 2 2 2 2 2 
2 3 1 0 1 3 0 2 2 2 2 1 0 1 1 2 0 2 2 2 2 2 1 2 1 
30 
16 10 13 niranjan 668369 f 4 1 2 2 2 1 2 2 
2 2 2 0 1 3 0 2 2 2 2 1 0 1 1 1 1 2 1 2 2 2 1 2 2 
  
 
 
